News ose-immuno-argacy-gineco Home > OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer > ose-immuno-argacy-gineco 27 August 2021
